Novel long-acting antagonists of muscarinic ACh receptors (original) (raw)
Effects of Pro-Leu-Gly-NH2 and cyclo (Leu-Gly) on the binding of 3H-quinuclidinyl benzilate to striatal cholinergic muscarinic receptors
Sanjoy Das
Peptides, 1986
View PDFchevron_right
Central versus peripheral effects of muscarinic antagonists: the limitations of quaternary ammonium derivatives
Paul Dudchenko
Psychopharmacology, 1992
View PDFchevron_right
Effect of dimethylamino-2-ethoxyimino-2-adamantane (CM 54903), a non-polar dimethylaminoethanol analog, on brain regional cholinergic neurochemical parameters
S. Garattini
Biochemical Pharmacology, 1982
View PDFchevron_right
The Selective M1 Muscarinic Cholinergic Agonist CDD-0102A Enhances Working Memory and Cognitive Flexibility
Michael Ragozzino
Journal of Pharmacology and Experimental Therapeutics, 2012
View PDFchevron_right
7-Chloro-3-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys
Alessandra Oberto
Proceedings of the National Academy of Sciences, 1995
View PDFchevron_right
Hydroxy Metabolites of the Alzheimer's Drug Candidate 3-[(2,4-Dimethoxy)Benzylidene]-Anabaseine Dihydrochloride (GTS-21): Their Molecular Properties, Interactions with Brain Nicotinic Receptors, and Brain Penetration
Laszlo Prokai
Molecular Pharmacology, 2004
View PDFchevron_right
Cognition Enhancing Profile of CR 2249, a New NMDA-Glycine Site Modulator
Marco Lanza
CNS Drug Reviews, 1997
View PDFchevron_right
Simplified analogs of himbacine displaying potent binding affinity for muscarinic receptors
alan kozikowski
Bioorganic & Medicinal Chemistry Letters, 1993
View PDFchevron_right
Therapeutic potential of CNS-active M2 antagonists: Novel structures and pharmacology
Michael Entzeroth
Life Sciences, 1993
View PDFchevron_right
Interaction of a new potent anticholinesterasic compound (±)huprine X with muscarinic receptors in rat brain
Nuria Vivas
Neuroscience Letters, 2002
View PDFchevron_right
Effect of novel arecoline thiazolidinones as muscarinic receptor 1 agonist in Alzheimer's dementia models
Manish Malviya
Neurochemistry International, 2008
View PDFchevron_right
The Pharmacology of GYKI-46 903, a New Cognition Enhancer
Ildikó Màté
CNS Drug Reviews, 1995
View PDFchevron_right
Effects of 5HT 6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat
Beatriz Marcos
British Journal of Pharmacology, 2008
View PDFchevron_right
Antagonism by antidepressants of muscarinic acetylcholine receptors of human brain
Elliott Richelson
British Journal of Pharmacology, 1983
View PDFchevron_right
In vivo neurochemical effects of the acetylcholinesterase inhibitor ENA713 in rat hippocampus
LUIGIA TRABACE
Brain research, 2000
View PDFchevron_right
{"__content__"=>"Assessment of the Molecular Mechanisms of Action of Novel 4-Phenylpyridine-2-One and 6-Phenylpyrimidin-4-One Allosteric Modulators at the M Muscarinic Acetylcholine Receptors.", "sub"=>{"__content__"=>"1"}}
Ben Capuano
Molecular pharmacology, 2018
View PDFchevron_right
Mapping muscarinic receptors in human and baboon brain using [N-11C-methyl]-benztropine
Jonathan Brodie
Synapse, 1990
View PDFchevron_right
Molecular requirements of the recognition site of cholinergic receptors. 27. Enantioselectivity of muscarinic antagonists. 2,2-Dicyclohexyl-5-[(dimethylamino)methyl]-1,3-oxathiolane methiodides and related 3-oxides
Fulvio Gualtieri
Journal of Medicinal Chemistry, 1988
View PDFchevron_right
de Bruin, Kruse - 2015 - 5-HT6 Receptor Antagonists Potential Efficacy for the Treatment of Cognitive.pdf
Natasja de Bruin
View PDFchevron_right
U-80816: A novel partial muscarinic agonist
Richard Heier
Drug Development Research, 1991
View PDFchevron_right
CI-1002: A Combined Acetylcholinesterase Inhibitor and Muscarinic Antagonist
Jeffrey Scholten
CNS Drug Reviews, 1995
View PDFchevron_right
Loss of muscarinic M4 receptors in hippocampus of Alzheimer patients 2003
Abdu Adem
View PDFchevron_right
Influence of the 5HT 6 Receptor on Acetylcholine Release in the Cortex: Pharmacological Characterization of 4-(2-Bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a Potent and Selective 5HT 6 Receptor Antagonist †
Claus Riemer, Edilio Borroni
Journal of Medicinal Chemistry, 2003
View PDFchevron_right
Inhibition of acetylcholine muscarinic M(1) receptor function 2000
Abdu Adem
View PDFchevron_right
Evidence for classical cholinergic toxicity associated with selective activation of M1 muscarinic receptors
Robert Gentles
The Journal of pharmacology and experimental therapeutics, 2015
View PDFchevron_right
The Potential for Muscarinic Receptor Subtype-Specific Pharmacotherapy for Alzheimer's Disease
Joseph T Coyle
Mayo Clinic Proceedings, 1991
View PDFchevron_right
Evaluation of brain pharmacokinetics of (+)MK-801 in relation to behaviour
Jens Nagel
Neuroscience Letters, 2011
View PDFchevron_right
{"__content__"=>"Probing the binding site of novel selective positive allosteric modulators at the M muscarinic acetylcholine receptor.", "sub"=>{"__content__"=>"1"}}
Celine Valant
Biochemical pharmacology, 2018
View PDFchevron_right
AC260584 (4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4 H-benzo[1,4]oxazin-3-one), a selective muscarinic M 1 receptor agonist, increases acetylcholine and dopamine release in rat medial prefrontal cortex and hippocampus
Douglas Bonhaus
Eur J Pharmacol, 2007
View PDFchevron_right